Reducing Benign Breast Biopsies in Women Aged 35 Years or Younger Using a Clinician–AI–Age Triage Strategy
Open Access
- 25 October 2026
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 16 (21) , 3491
Abstract
Background/Objectives: Symptomatic breast services face increasing diagnostic demand, while younger women with benign-appearing ultrasound lesions frequently undergo biopsy despite a low prevalence of malignancy. This study evaluated whether a rule-based clinical decision algorithm combining patient age, clinician ultrasound assessment and artificial intelligence (AI) decision support could identify a subgroup in whom biopsy might be avoided without excluding malignancy from the biopsy pathway. Methods: A retrospective analysis was performed using prospectively collected service-evaluation data from 240 patients (254 lesions) attending a large NHS breast unit between May and December 2025. Clinician ultrasound assessment, KOIOS DS Breast AI output and histopathology were recorded. Lesions in women aged ≤ 35 years were eligible for biopsy avoidance when clinician assessment was U2 or U3 and the KOIOS AI assessment was BI-RADS 2. Histopathology was the reference standard. Secondary analyses compared clinician and AI diagnostic performance. An illustrative five-year budget impact analysis was undertaken from the NHS provider perspective. Results: Among 151 lesions in women aged ≤ 35 years, 146 were benign and five were malignant. The algorithm would have classified 87 lesions for biopsy avoidance (57.6%; 95% CI, 49.3–65.6%). Of these, 67 (77.0%) had a clinician U3 classification. All 87 were benign on histopathology (100%; 95% CI, 95.8–100%), while all five malignant lesions remained in the biopsy pathway. Clinician assessment showed higher specificity than AI (99.1% vs. 75.7%), whereas AI showed higher sensitivity (96.9% vs. 81.3%). Avoidance of 87 biopsies was associated with approximately £85,000 in gross cost offsets during the evaluation period in the illustrative economic model. Conclusions: The AI-supported clinical decision algorithm could substantially reduce benign biopsy activity in younger women while maintaining cancer detection in this cohort. The small number of malignancies, single-centre design and biopsy population mean that prospective multicentre validation is required before routine clinical implementation.Keywords
Funding Information
- Koios Medical
This publication has 13 references indexed in Scilit:
- The STARD-AI reporting guideline for diagnostic accuracy studies using artificial intelligenceNature Medicine, 2025
- Non-biopsy of fibroadenomas in the UK and Ireland: a British Society of Breast Radiology survey of national practiceClinical Radiology, 2025
- Checklist for Artificial Intelligence in Medical Imaging (CLAIM): 2024 UpdateRadiology: Artificial Intelligence, 2024
- Artificial Intelligence in BI-RADS Categorization of Breast Lesions on Ultrasound: Can We Omit Excessive Follow-ups and Biopsies?Academic Radiology, 2023
- Combining the strengths of radiologists and AI for breast cancer screening: a retrospective analysisThe Lancet Digital Health, 2022
- Artificial intelligence system reduces false-positive findings in the interpretation of breast ultrasound examsNature Communications, 2021
- Audit of eliminating biopsy for presumed fibroadenomas with benign ultrasound greyscale and shear-wave elastography findings in women aged 25–39 yearsClinical Radiology, 2020
- Should We Ignore, Follow, or Biopsy? Impact of Artificial Intelligence Decision Support on Breast Ultrasound Lesion AssessmentAmerican Journal of Roentgenology, 2020
- Psychological consequences of false-positive screening mammograms in the UKBMJ Evidence-Based Medicine, 2012
- Quantification of the UK 5-point breast imaging classification and mapping to BI-RADS to facilitate comparison with international literatureBritish Journal of Radiology, 2011